NASDAQ:CATB - Catabasis Pharmaceuticals, Inc.
$4.45
 $0.02
+0.45%
2:30PM EDT
2019-02-15
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CATB     avg for
industry  
  avg for
sector  
42 stocks weight:  63. 25   0. 00   0. 00  
42 stocks rank:  2. 42 K 1. 86 K 1. 09 K
# analyst opinions:  3. 00   14. 92   14. 43  

quick ratio:  10. 48   5. 37   1. 81  
current ratio:  10. 80   5. 69   2. 19  

target price low:  4. 77   88. 97   117. 82  
target price avg:  4. 00   115. 19   141. 96  
target price high:  7. 70   143. 40   163. 16  
1-yr high:  20. 50   124. 30   142. 77  
last close:  4. 43   101. 85   127. 84  
50-day avg:  5. 32   98. 27   122. 46  
200-day avg:  8. 31   99. 72   122. 70  
1-yr low:  0. 41   78. 19   100. 16  
volume:  147. 31 K 2. 38 M 4. 64 M
50-day avg volume:  328. 21 K 3. 31 M 4. 94 M
200-day avg volume:  684. 65 K 3. 23 M 4. 28 M

1-day return:  0. 91 % 0. 22 % 0. 48 %
this week return:  1. 84 % 1. 77 % 2. 01 %
12-wk return:  -22. 28 % 6. 56 % 3. 33 %
52-wk return:  -68. 42 % -2. 23 % 14. 35 %

enterprise value (EV):  -12. 05 M 55. 17 B 104. 51 B
market cap:  49. 36 M 49. 01 B 96. 46 B
EBITDA:  -24. 67 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  0. 49   -91. 79   2. 29  
enterprise/revenue (EV/R):  -48. 21   29. 84   23. 39  
total revenue:  250. 00 K 11. 28 B 40. 22 B
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -25. 31 M 2. 37 B 3. 58 B

shares outstanding:  11. 14 M 607. 99 M 1. 22 B
shares:  7. 09 M 605. 53 M 1. 15 B
shares short:  204. 99 K 11. 62 M 12. 55 M
shares short prior month:  60. 51 K 11. 95 M 13. 44 M
short ratio:  1. 43   4. 82   3. 10  
short % of float:  3. 69 % 6. 19 % 2. 82 %
total cash/share:  6. 09   12. 02   11. 46  
total cash:  43. 24 M 7. 41 B 7. 37 B
free cash flow:  -13. 96 M 95. 99 M 2. 04 B
operating cash flow:  -23. 83 M 164. 74 M 3. 04 B

book value:  5. 70   14. 43   28. 26  
price/book:  0. 78   -1. 57   -2. 97  
gross profits:  500. 00 K 8. 28 B 18. 09 B
operating margins:  -9938. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  100. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  -89. 80 % --- ---
1-yr mean volatility:  -0. 76 % 0. 01 % 0. 06 %

1-yr EPS:  -6. 57   3. 03   4. 09  
forward EPS:  -3. 78   4. 33   6. 99  
P/E:  -0. 67   6. 11   26. 91  
forward P/E:  -1. 17   8. 38   10. 48  
PE/G:  0. 01   0. 37   5. 61  
growth:  -48. 54 % 683. 72 % 104. 79 %
earnings high:  -0. 85   1. 27   1. 66  
earnings avg:  -0. 92   1. 01   1. 53  
earnings low:  -1. -1   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -45. 66 % -3. 27 % 3. 81 %
return on equity:  -90. 10 % 107. 48 % 27. 82 %
revenue/share:  0. 07   14. 68   59. 83  

beta (1yr vs S&P500):  0. 68   1. 21   0. 93  
sharpe (1yr):  -1. 67   0. 06   0. 98  

held % insiders:  1. 93 % 6. 46 % 3. 21 %
held % institutions:  22. 94 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : CATB
.        + 0 =             0 :: INITIAL WEIGHT
. + 18849.06 =      18849.06 :: inverse volume-to-price addition
.   + 387.09 =      19236.15 :: spline projection addition
.  - 224.184 =     19011.966 :: poor performance penalty
.    x 0.557 =     10598.635 :: one-year gains+dividend factor
.    x 1.687 =     17881.036 :: 13 weeks' performance factor
.    x 1.492 =     26687.247 :: industry recommendation factor
.    x 0.995 =     26565.385 :: return on assets factor
.    x 0.991 =     26326.033 :: return on equity factor
.    x 2.103 =     55376.102 :: current ratio factor
.    x 1.051 =     58222.987 :: quick ratio factor
.    x 1.304 =     75897.872 :: short ratio factor
.    x 2.008 =    152385.204 :: price-to-book factor
.    x 5.616 =    855799.144 :: EBITDA multiple factor
.    x 2.173 =    1859798.17 :: P/E weight
.    x 2.209 =   4108218.117 :: PE/G factor
.    x 1.579 =   6485104.669 :: beta factor
.    x 0.357 =   2315368.704 :: sharpe factor
.     x 1.28 =   2963556.071 :: target low factor
.    x 0.945 =   2799904.398 :: target mean factor
.    x 1.086 =   3040459.857 :: target high factor
.    x 1.066 =   3239952.962 :: industry 12-weeks return
.      x 1.0 =   3239565.193 :: overall "drift" factor
.    x 0.996 =   3226635.728 :: largest single-day jump factor
.    x 0.078 =    253069.469 :: low price factor
.      x 1.0 =    253086.456 :: factor hist industry gain for week 06
.   cubeRoot =        63.254 :: reduced for readability
.                     63.254 :: FINAL WEIGHT for NASDAQ:CATB


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org